Veozah vs. estradiol: does the non-hormonal option really work as well as HRT?

Does Veozah work as well as estradiol for hot flashes?

Start with what The Menopause Society itself says, because it settles the broad question quickly: systemic hormone therapy, with or without progestin, is the most effective treatment for vasomotor symptoms, and its 2022 position statement notes that the various formulations, doses, and routes of estrogen therapy all deliver comparably high efficacy. In a commonly cited randomized trial of combined estrogen-progestin therapy, hot flash frequency fell by about 74% from baseline, compared with roughly 51% on placebo — a wide, reliable margin that has held up across decades of hormone therapy research.

Veozah's own trial record is genuinely strong, just measured differently. The phase 3 SKYLIGHT 1 trial, published in The Lancet, enrolled women averaging 10 to 12 moderate-to-severe hot flashes a day. On the 45mg dose, fezolinetant cut that frequency by 2.07 episodes a day more than placebo at week 4, and by 2.55 episodes a day more than placebo at week 12 — clearing the FDA's own bar for a clinically meaningful benefit, a reduction of at least 2 hot flashes daily. That improvement held through 52 weeks, and discontinuation rates due to side effects were close to placebo, meaning most women who started it stayed on it.

There's no published trial that puts Veozah and estradiol head-to-head in the same women, so any comparison is really two separate placebo comparisons laid side by side, not an apples-to-apples race. With that caveat honestly stated, the pattern in the literature is consistent: hormone therapy produces a larger, more reliable reduction in hot flash frequency and severity than Veozah does. That doesn't make Veozah a weak option — it made it through FDA review specifically because its effect was real and statistically solid — it just means the more accurate framing is "a genuinely effective non-hormonal alternative," not "an equal substitute."

How Veozah and HRT actually work — and why the mechanism matters

The two drugs solve the same symptom through opposite strategies, and that difference explains almost everything else in this comparison. Veozah (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist. It blocks a signaling pathway in the hypothalamus — the brain's temperature-control center — that goes into overdrive as estrogen declines and triggers the erratic heat surges you feel as a hot flash. It contains no estrogen, no progesterone, and no hormone of any kind.

Hormone therapy takes the more direct route: it replaces the estrogen your ovaries have stopped making (plus progesterone, if you still have a uterus, to protect the uterine lining). Because it addresses the underlying hormonal decline rather than one downstream symptom, HRT's reach extends further — bone density, vaginal and urinary tissue, sleep architecture, and mood all respond to estrogen in ways a hot-flash-specific drug simply isn't built to touch. Veozah is a precision tool for one symptom cluster; HRT is a broader intervention with a broader risk profile to match. For the fuller picture of what HRT actually involves during this specific life stage — timing, options, and how it differs from postmenopausal HRT — see hormone therapy in perimenopause.

Is Veozah safer than HRT? What the boxed liver warning actually means

This is usually the first question women ask once they hear "non-hormonal," and it deserves a direct answer: not automatically. On December 16, 2024, the FDA added a boxed warning — its most serious labeling action — to Veozah for rare but serious liver injury. The warning followed a postmarketing case: a patient developed fatigue, nausea, itching, jaundice, pale stools, and dark urine within 40 days of starting the drug, with clearly abnormal liver enzymes and bilirubin that returned to normal after she stopped taking it.

In practical terms, that warning changed what's required before and during treatment. Prescribers now check liver function tests at baseline, then again at months 1 and 2, and again at months 3, 6, and 9. Veozah is contraindicated outright in anyone with cirrhosis — including the mildest classification, Child-Pugh Class A — and in anyone taking a strong CYP1A2 inhibitor such as fluvoxamine, which in trial data raised fezolinetant exposure by more than 800%. For a woman with normal baseline liver function and no interacting medications, the absolute risk stays low. It isn't, however, a label formality to skim past — watch for fatigue, yellowing skin or eyes, dark urine, or unusual abdominal pain, and stop the drug and call your clinician if any of those show up.

What are HRT's risks, and who shouldn't take it?

HRT's risk profile is the mirror image: better studied, generally low, but real and non-negotiable for certain histories. ACOG and The Menopause Society both name the same core contraindications — a personal history of breast cancer (particularly estrogen-sensitive disease), unexplained vaginal bleeding, active liver or gallbladder disease, and a personal history of venous thromboembolism (a DVT or pulmonary embolism) unless you're already anticoagulated.

For women without those contraindications, NAMS's 2022 position statement frames the numbers as small: estrogen-only therapy carries roughly 11 additional cases of blood clots per 10,000 woman-years, combined estrogen-progestin therapy runs closer to 21, stroke risk in women under 60 adds about one extra case per 1,000 women over five years of use, and breast cancer risk with combined therapy adds fewer than one additional case per 1,000 woman-years. Route changes that math meaningfully: oral estrogen passes through the liver first and raises clotting factors more than transdermal delivery does, so a patch, gel, or cream carries a lower clot and stroke risk than a pill — which is exactly why NAMS and ACOG both favor transdermal routes for women who already carry some clotting risk. Timing matters too. Starting hormone therapy within about ten years of your last period, and before age 60, is consistently linked to the most favorable risk-benefit balance in the research both societies reviewed.

Side effects day to day: what to actually expect on each

Set the boxed-warning and contraindication conversations aside for a moment, because both drugs also come with an ordinary, much more common list of things your body might do in the first few weeks.

• Veozah's most common side effects, per its FDA label: stomach or abdominal pain, diarrhea, difficulty sleeping, back pain, and — somewhat counterintuitively — a transient increase in hot flushes
• HRT's most common side effects: breast tenderness or swelling, bloating, breakthrough bleeding or spotting (especially in the first few months), headaches, and nausea, particularly with oral estrogen
• Both patterns tend to ease over the first three to six months as your body adjusts, and a side effect that hasn't budged by then is the signal to ask about a dose or formulation change rather than waiting longer

For the fuller breakdown of HRT's early side effects, what's normal versus what needs a same-day call, and how hair and skin respond to estrogen specifically, see HRT side effects.

Who is Veozah actually for, and who is HRT actually for?

Put the mechanism and the safety data together and the candidacy picture gets clearer than either topic looks on its own.

• Veozah tends to make the most sense for: women with a history of estrogen-sensitive breast cancer who can't use hormones at all (Veozah itself was studied mainly outside this population, so this specific decision belongs with your oncologist); women with a personal or family history of blood clots that makes systemic estrogen a higher-risk conversation; women who tried HRT and didn't tolerate it; women with normal liver function who simply prefer a non-hormonal approach; and women whose main complaint is hot flashes and night sweats specifically, without a strong need for bone, vaginal, or mood support
• HRT tends to make the most sense for: women within about ten years of their last period or under 60 with no contraindications above; women who want the strongest available reduction in hot flash frequency and severity; and women who also need the broader benefits estrogen provides — bone density protection, relief from vaginal and urinary symptoms, and often better sleep — that Veozah isn't approved to address
• Neither drug is a great fit for active liver or gallbladder disease — HRT is contraindicated there directly, and Veozah is contraindicated in cirrhosis specifically, so a significant liver history is worth raising early in either conversation, not after a prescription is already written

For the wider landscape beyond just these two — SSRIs, gabapentin, clonidine, and lifestyle approaches — see menopause treatment options. For HRT's actual dosing ranges by route, see HRT dosage.

How much does each one cost in 2026?

The sticker prices sit at opposite ends of the spectrum, and insurance changes both numbers dramatically. Veozah lists at $583.50 a month, but pharmacy counters typically charge about $773 in cash, with a GoodRx or SingleCare coupon bringing that down to roughly $467 a month at Walmart and $473 to $488 at Walgreens or CVS, depending on where you fill it. For commercially insured patients, the Astellas manufacturer copay card is the number that actually matters: the first month free, then roughly $30 a month after, capped at $4,000 in assistance per year. That card excludes Medicare, Medicaid, and Tricare entirely. Astellas reports that around 88% of commercial covered lives have some level of coverage as of December 2025, though a real share of that requires prior authorization or step therapy — commonly, documentation that HRT was tried first or ruled out. There's no generic fezolinetant; the patent runs to roughly 2034. Full detail lives at Veozah's real 2026 cost.

Estradiol's price range is much wider because it isn't one product. A generic oral estradiol tablet with a GoodRx or SingleCare coupon can run as low as roughly $9 to $16 a month; a generic patch with a coupon runs closer to $36 to $71. Through telehealth, Winona prices its FDA-approved estradiol patch, tablets, and progesterone à la carte from $39 a month with no consult fee, while Alloy charges a one-time $49 consult plus $100 a month for its estradiol patch, with progesterone priced separately from $23 a month. Midi Health's self-pay visit runs $250 initial and $150 for follow-ups, but it's one of the few options here that regularly bills PPO insurance, which can bring that down to a standard specialist copay. The full seven-provider breakdown, including hidden fees, is at how much HRT costs and the cheapest ways to get HRT.

Annualized, the gap is stark. Veozah at cash price runs about $9,264 to $9,336 a year; with the copay card, closer to $330. A retail-pharmacy generic estradiol-and-progesterone protocol can total as little as roughly $276 to $540 a year with a coupon; Alloy's patch-and-progesterone protocol lands around $1,525 in year one. For a woman who's a candidate for either drug and has commercial insurance behind her, the real-world cost comparison often has less to do with the drug itself and more to do with whether a copay card or a formulary applies — worth confirming before the price alone rules an option out.

Can you switch between them, or use both together?

Switching is common and, in practice, often insurance-driven as much as clinically driven: plenty of women start on HRT, find it isn't tolerated or isn't appropriate later, and move to Veozah — and that sequence lines up with how a lot of insurers structure step therapy anyway, requiring a documented HRT trial or contraindication before approving Veozah. The reverse also happens — a woman starts on Veozah because she assumed hormones were off the table, then learns in a fuller workup that she's actually a reasonable HRT candidate after all.

Combining them is a different question, and a much less settled one. Because the two drugs act on different pathways — NK3 receptor blockade versus hormone replacement — there's no obvious pharmacological conflict, but Veozah was studied and approved as monotherapy, not as an add-on to hormone therapy, so there isn't a substantial trial record for using both together. If hot flashes are only partially controlled on one and you're weighing the other, that's a conversation to have with your prescriber about your specific situation rather than a combination to start on your own.

So which one should you actually start with?

If you can't be honest with a checklist about your own history, none of the trial data above will point you anywhere useful — so start there before the mechanism debate. A few questions do most of the sorting.

• Do you have a history of breast cancer, an unexplained bleeding pattern, active liver disease, or a personal history of blood clots? If yes, that likely steers you toward Veozah or a non-hormonal path — and toward a specialist conversation either way
• Are you within about ten years of your last period, under 60, and free of the contraindications above? HRT is generally the more effective starting point for hot flashes specifically, per NAMS's own framing
• Is your only real complaint hot flashes and night sweats, with no strong need for bone, vaginal, or sleep support? Veozah's narrower scope may be a fair trade for skipping hormones
• Does your liver function test come back normal, and are you not on a strong CYP1A2 inhibitor like fluvoxamine? That's what actually clears Veozah as an option, not preference alone
• What does your insurance actually require — a documented HRT trial before it'll cover Veozah, or vice versa? That paperwork reality sometimes decides the starting order regardless of which drug you'd pick on medical grounds alone

Neither answer is permanent. A prescription that doesn't fit at 47 can look different at 52, and switching lanes is a normal part of managing this transition rather than a sign the first choice was wrong.